Pharma Journalist -

Bayer Inc. announced that Health Canada approved finerenone, under the brand name KERENDIA, as an adjunct to standard of care therapy in adults with chronic kidney disease (CKD) and…
Read More...

Normunity, Inc., a biotechnology company creating novel precision anti-cancer immunotherapies, announced its launch and Series A financing of $65 million. The Series A was led by Canaan…
Read More...

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure across the globe, announced that the Company made a new…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI (teclistamab-cqyv) for the treatment of adult…
Read More...

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced a strategic…
Read More...

BioMed X announced the launch of their first joint research project with Sanofi. As part of this, a new research group to be established at the BioMed X Institute in Heidelberg,…
Read More...

AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma…
Read More...

Astellas Pharma Inc. and Taysha Gene Therapies, Inc. announced a strategic investment to support the advancement of Taysha's adeno-associated virus (AAV) gene therapy development…
Read More...

SAE Media Group reports: The 14th Annual RNA Therapeutics Conference is set to return in February 2023 with a key focus on mRNA therapeutic applications. SAE Media Group is delighted…
Read More...

Daiichi Sankyo received notification of acceptance by the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) of quizartinib in combination with standard…
Read More...